KINECT-Next : A Study of NBI-1065890 in Adult Participants With Tardive Dyskinesia

KINECT-Next : A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

Tardive dyskinesia: Let us help you face a future where you may be more in control

The KINECT-Next™ Study is being conducted to find out whether an investigational drug may help reduce symptoms in people with a psychiatric condition who are experiencing sudden, irregular movements known as tardive dyskinesia (TD).

The study will also evaluate the investigational drug’s safety and monitor for any potential side effects.

We are looking for people who:

• Are aged 18–75 years
• Have been diagnosed with TD
• Have been diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder.

Participants may be compensated for time and reasonable expenses related to the study.